Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,637 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pancreatic Cysts.
Hamada T, Oyama H, Nakai Y; TOP-CREATE Study Group. Hamada T, et al. N Engl J Med. 2024 Nov 28;391(21):2063-2064. doi: 10.1056/NEJMc2412611. N Engl J Med. 2024. PMID: 39602646 No abstract available.
ABO Blood Group and Risk of Pancreatic Carcinogenesis in Intraductal Papillary Mucinous Neoplasms.
Hamada T, Oyama H, Nakai Y, Tada M, Koh H, Tateishi K, Arita J, Hakuta R, Ijichi H, Ishigaki K, Kawaguchi Y, Kogure H, Mizuno S, Morikawa T, Saito K, Saito T, Sato T, Takagi K, Takahara N, Takahashi R, Tanaka A, Tanaka M, Ushiku T, Hasegawa K, Koike K. Hamada T, et al. Cancer Epidemiol Biomarkers Prev. 2021 May;30(5):1020-1028. doi: 10.1158/1055-9965.EPI-20-1581. Epub 2021 Mar 2. Cancer Epidemiol Biomarkers Prev. 2021. PMID: 33653811
A phase II trial of gemcitabine, S-1 and LV combination (GSL) therapy in patients with advanced pancreatic cancer.
Saito K, Isayama H, Nakai Y, Takahara N, Ishigaki K, Takeda T, Hakuta R, Saito T, Uchino R, Kishikawa T, Hamada T, Mizuno S, Sasaki T, Kogure H, Matsubara S, Yamamoto N, Ijichi H, Tateishi K, Tada M, Koike K. Saito K, et al. Among authors: hamada t. Invest New Drugs. 2019 Apr;37(2):338-344. doi: 10.1007/s10637-018-0691-9. Epub 2018 Nov 9. Invest New Drugs. 2019. PMID: 30411217 Clinical Trial.
A phase I study of intraperitoneal paclitaxel combined with gemcitabine plus nab-paclitaxel for pancreatic cancer with peritoneal metastasis.
Takahara N, Nakai Y, Ishigami H, Saito K, Sato T, Hakuta R, Ishigaki K, Saito T, Hamada T, Mizuno S, Kogure H, Yamashita H, Isayama H, Seto Y, Koike K. Takahara N, et al. Among authors: hamada t. Invest New Drugs. 2021 Feb;39(1):175-181. doi: 10.1007/s10637-020-00982-7. Epub 2020 Aug 8. Invest New Drugs. 2021. PMID: 32772340 Clinical Trial.
A retrospective comparative study of S-IROX and modified FOLFIRINOX for patients with advanced pancreatic cancer refractory to gemcitabine plus nab-paclitaxel.
Saito K, Nakai Y, Takahara N, Ishigaki K, Suzuki Y, Inokuma A, Noguchi K, Kanai S, Sato T, Hakuta R, Saito T, Hamada T, Mizuno S, Kogure H, Ijichi H, Tateishi K, Koike K. Saito K, et al. Among authors: hamada t. Invest New Drugs. 2021 Apr;39(2):605-613. doi: 10.1007/s10637-020-01022-0. Epub 2020 Oct 23. Invest New Drugs. 2021. PMID: 33094362
Screening Strategy of Pancreatic Cancer in Patients with Diabetes Mellitus.
Mizuno S, Nakai Y, Ishigaki K, Saito K, Oyama H, Hamada T, Suzuki Y, Inokuma A, Kanai S, Noguchi K, Sato T, Hakuta R, Saito T, Takahara N, Kogure H, Isayama H, Koike K. Mizuno S, et al. Among authors: hamada t. Diagnostics (Basel). 2020 Aug 8;10(8):572. doi: 10.3390/diagnostics10080572. Diagnostics (Basel). 2020. PMID: 32784500 Free PMC article. Review.
2,637 results